Humanized anti-Lewis Y antibodies: In vitro properties and pharmacokinetics in rhesus monkeys

Cancer Research

Volumn 56, Issue 5, 1996, Pages 1118-1125

  Co, Man Sung ^a   Baker, Jeanne ^a   Bednarik, K ^b   Janzek, E ^b   Neruda, W ^b   Mayer, P ^b   Plot, R ^b   Stumper, B ^b   Vasquez, Max ^a   Queen, Cary ^a   Loibner, Hans ^b  

^a PROTEIN DESIGN LABS INC   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; BLOOD GROUP LEWIS SYSTEM; BREAST CANCER; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOLYSIS; EFFECTOR CELL; GENETIC COMPLEMENTATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; RHESUS MONKEY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; CELLS, CULTURED; DNA, COMPLEMENTARY; HUMANS; LEWIS BLOOD-GROUP SYSTEM; LYMPHOCYTE ACTIVATION; MACACA MULATTA; MICE; MOLECULAR SEQUENCE DATA; RECOMBINANT FUSION PROTEINS;

EID: 0003404076     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Blaszczyk-Thurin, M., Thurin, J., Hindsgaul, O., Karlsson, K., Steplewski, Z., and Koprowski, H. Y and blood group B type 2 glycolipid antigens accumulate in a human gastric carcinoma cell line as detected by monoclonal antibody. J. Biol. Chem., 262: 372-379, 1987.
2. Steplewski, Z., Blaszczyk-Thurin, M., Lubeck, M., Loibner, H , Scholz, D., and Koprowski, H. Oligosaccharide Y specific monoclonal antibody and its isotype switch variants. Hybridoma, 9: 201-210, 1990
3. b antigens with survival in patients with carcinoma of the lung. N. Engl. J. Med., 327: 14-18, 1992.
4. y-related cell surface antigens. Cancer Res., 50: 2183-2190, 1990.
5. y determinants. Proc. Natl. Acad. Sci. USA, 91: 12957-12961, 1994
6. Scholz, D., Lubeck, M., Loibner, H., McDonald-Smith, J., Kimoto, Y., Koprowski, H., and Steplewski, Z Biological activity in the human system of isotype variants of oligosaceharide-Y-specific murine monoclonal antibodies. Cancer Immunol. Immunother., 33: 153-157, 1991.
7. Steplewski, Z., Lubeck, M. D., Scholz, D. Loibner, H., Smith, J. M., and Koprowski, H. Tumor cell lysis and tumor growth inhibition by the isotype variants of Mab BR55-2 directed against Y oligosaccharide. In Vivo, 5: 79-84, 1991
8. Stahel, R. A , Lacroix, H., Sculier, J. P., Morant, R., Richner, J., Janzek, E., Loibner, H., and Blythman, H. Phase I/II study of monoclonal antibody against Lewis Y hapten in relapsed small-cell lung cancer Ann Oncol., 3: 319-320, 1992.
9. Schlimok, G., Fackler-Schwalbe, I., Pantel, K., Loibner, H., and Riethmuller, G. Monoclonal Lewis Y antibody depletes metastatic breast carcinoma cells from bone marrow. Proc. Am. Soc. Clin. Oncol., 12: 939, 1993.
10. Schroff, R W , Foon, K. A., Beatty, S. M., Olkham, R. K., and Morgan, A. C., Jr. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res , 45: 879-885, 1985.
11. Shawler, D. L , Bartholomew, R M., Smith, L. M., and Dillman, R. O. Human immune response to multiple injections of murine monoclonal IgG. J. Immunol., 135: 1530-1535, 1985.
12. Khazaeli, M. B., Saleh, M N., Wheeler, R. H , Huster, W. J., Holden, H , Carrano, R , and LoBuglio, A F Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A II. Pharmacokinetics and immune response. J Natl Cancer Inst, 80 937-942, 1988.
13. Morell, A., Terry, W. D., and Waldmann, T. A. Metabolic properties of IgG subclasses in man J Clin. Invest , 49: 673-680, 1970
14. Liu, A. Y., Robinson, R. R., Hellstrom, K. E., Murray, E. D , Jr., Chang, C. P., and Hellstrom, I. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc. Natl. Acad. Sci. USA, 84: 3439-3444, 1987.
15. Junghans, R. P., Waldmann, T. A., Landolfi, N. F., Avdalovic, N M., Schneider, W. P., and Queen, C. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res., 50: 1495-1502, 1990.
16. Morrison, S. L., Johnson, M. J., Herzenberg, L. A , and Oi, V T. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad Sci. USA, 81: 6851-6855, 1984.
17. Bruggemann, M., Winter, G., Waldmann, H , and Neuberger, M. S The immunogenicity of chimeric antibodies. J Exp. Med., 170: 2153-2157, 1989.
18. Riechmann, L , Clark, M., Waldmann, H., and Winter, G. Reshaping human antibodies for therapy. Nature (Lond ), 332: 323-327, 1988
19. Co, M. S., Avdalovic, N M., Caron, P. C , Avdalovic, M. V., Scheinberg, D. A., and Queen, C. Chimeric and humanized antibodies with specificity for the CD33 antigen J Immunol., 138: 1149-1154, 1992
20. Berzofsky, J A., and Berkower, I. J. Immunogenicity and antigen structure. In: W. E. Paul (ed.), Fundamental Immunology, pp. 595-644. New York: Raven Press, 1984.
21. 125I-containing acylating agent. Biochem. J., 133: 529-539, 1973
22. Loibner, H., Jaksche, H , Janzek, E , Plot, R., and Putsch, E. A monoclonal antiidiotypic antibody that mimics the Lewis Y carbohydrate antigen - crossreactivity to a CDR-grafted version of Ab1 as proof of internal image properties. J. Immunother., 14: 357, 1993.
23. Queen, C., Schneider, W. P., Selick, H E., Payne, P. W., Landolfi, N. R. Duncan, J. F., Avdalovic, N. M., Levitt, M., Junghans, R. P., and Waldmann, T. A. A humanized antibody that binds to the interleukin-2 receptor. Proc Natl. Acad. Sci. USA, 86: 10029-10033, 1989.
24. Zilber, B , Scherf, T., Levitt, M., and Anglister, J. NMR-derived model for a peptide-antibody complex. Biochemistry, 29: 10032-10041, 1990
25. Kabat, E. A., Wu, T T., Reid-Miller, M., Perry, H. M., and Gottesman, K. S. Sequences of Proteins of Immunological Interest, 5th ed. Bethesda, MD: U. S. Department of Health and Human Services, 1991.
26. Brüggemann, M., Williams, G., Bindon, C. I , Clark, M. R., Walker, M. R. Jefferis, R., Waldmann, H., and Neuberger, M. S. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp. Med., 166: 1351-1361, 1987
27. Steplewski, Z , Sun, L. K., Shearman, C. W , Ghrayeb, J., Doddona, P., and Koprowski, H. Biological activity of human-mouse IgG1, IGg2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc. Natl. Acad. Sci USA, 85: 4852-4856, 1988.
28. Shaw, D. R., Kharaeli, M. B., and LoBuglio, A. F. Mouse/human chimeric antibodies to a tumor-associated antigen: biologic activity of the four human IgG subclasses. J. Natl. Cancer Inst., 80: 1553-1559, 1988
29. Schreiber, G. J., Hellstrom, K. E., and Hellström, I. An unmodified anticarcinoma antibody, BR96, localized to and inhibits the outgrowth of human tumors in nude mice Cancer Res., 52: 3262-3266, 1992.
30. Greenspan, N. S., and Cooper, L. J N. Intermolecular cooperativity, a clue to why mice have IgG3. Immunol Today, 13 164-168, 1992.
31. Michaelsen T. E., Garred, P., and Aase, A. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur. J. Immunol , 21: 11-16, 1991.
32. Shalaby, M. R., Shepard, H M., Presta, L., Rodrigues, M. L., Beverley, P. C. L., Feldmann, M., and Carter, P. Development of humanized bispecific anybodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J. Exp Med., 175: 217-225, 1992.
33. Tempest, P. R., Bremner, P., Lambert, M., Taylor, G., Furze, J. M., Carr, F. J., and Harris, W. J. Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Biotechnology, 9: 266-271, 1991.
34. Co, M. S., Deschamps, M., Whitley, R. J , and Queen, C. Humanized antibodies for antiviral therapy. Proc. Natl. Acad Sci. USA, 88: 2869-2873, 1991.
35. Co, M. S., Yano, S., Hsu, R. K., Landolfi, N F. Vasquez, M., Cole, M., Tso, J., Bringman, T , Laird, W., Hudson, D., Kawamura, K., Suzuki, K , Furuichi, K., Queen, C., and Masuho, Y. A humanized antibody specific for the platelet integrin gpIIb/IIIa. J. Immunol , 152: 2968-2976, 1994.
36. Hellstrom, K. E., and Hellstrom, I. In: C A. K Borrebaeck and J W. Larrick (eds.), Mouse antibodies to carcinomas. Therapeutic Monoclonal Antibodies, pp. 91-108. New York: Stock Press, 1990.
37. Yelton, D E., Rosok, M. J , Cruz, G , Cosand, W. L., Bajorath, J., Hellström, I., Hellstrom, K E., Huse, W. D., and Glaser, S. M. Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis. J Immunol , 155: 1994-2004, 1995.
38. Wu, G. E , Hozumi, N , and Murialdo, H. Secretion of a λ2 immunoglobulin chain is prevented by a single amino acid substitution in its variable region. Cell, 33, 77-83, 1983.
39. Dul, J. L., Burrone, O R., and Argon, Y. A conditional secretory mutant in an Ig L chain is caused by replacement of tyrosine/phenylalanine 87 with histidine J. Immunol., 149: 1927-1933, 1992.
40. Dul, J L., and Argon, Y. A single amino acid substitution in the variable region of the light chain specifically blocks immunoglobulin secretion. Proc. Natl. Acad. Sci. USA, 87: 8135-8139, 1990
41. Friedman, P. N., McAndrew, S. J., Gawlak, S. L., Chace, D., Trail, P A., Brown, J P , and Siegall, C. B. BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells. Cancer Res., 53: 334-339, 1993.
42. Trail, P A , Willner, D., Lach, S. J., Henderson, A. J., Hofstead, S , Casazza, A M., Frrestone, R. A., Hellstrom, I., and Hellstrom, K. E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science (Washington DC), 261: 212-215, 1993.
43. Anasetti, C., Hanse, J. A , Waldmann, T A , Appelbaum, F. R., Davis, J., Deeg, H. J., Doney, K , Martin, P. J., Nash, R., Storb, R., Sullivan, K M., Witherspoon, R. P., Binger, M , Chizzonite, R., Hakinu, J , Mould, D., Satoh, H., and Light, S. E. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor Blood, 84: 1320-1327, 1994
44. Caron, P. C , Jurcic, J. G., Scott, A. M., Finn, R. D., Divgi, C. R , Graham, M C., Jureidini, I M., Sgouros, G., Tyson, D., Old, L J., Larson, S. M , and Scheinberg, D. A A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogeniciry. Blood, 83: 1760-1768, 1994.
45. Azuma, J., Kurimoto, T., Tsuju, S., Mochizuki, N., Fujinaga, S , Mastsumoto, Y , and Masuho, Y. Phase I study on human monoclonal antibody against cytomegalovirus: pharmacokinetics and imnumogenicity J. Immunother , 10, 278-285, 1991.
46. Drobyski, W., Gottlieb, M., Carrigan, D., Ostberg, L , Grebenau, M., Schran, H., Magid, P., Ehrlich, P., Nadler, P I., and Ash, R. C Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients. Transplantation, 51: 1190-1196, 1991